摘要
目的 观察健择、卡铂联合治疗非小细胞肺癌的疗效和毒性。方法 对 5 0例Ⅲb～Ⅳ期非小细胞肺癌患者采用随机、双盲方法分为治疗组 2 5例 ,对照组 2 5例 ,治疗组采用健择 10 0 0mg/m2 第 1、8天静脉滴注 ,卡铂 30 0mg/m2 第 1天静脉滴注 ,4周为一周期 ;对照组足叶乙甙 0 .1/m2 第 1、2、3天静脉滴注 ,卡铂30 0mg/m2 第 1天静脉滴注 ,3周为 1周期 ;2周期后评价疗效。结果 治疗组 2 5例可评价疗效 ,完全缓解 6例 ,部分缓解 8例 ,总有效率 5 6 % ,中位缓解期 3.8月 ;对照组 2 5例可评价疗效 ,完全缓解 2例 ,部分缓解 7例 ,有效率 36 %。结论 健择。
Objective To observe the effect and toxicity of gemcitabine and carboplatin on non-small cell lung cancer patients.Methods Fifty Ⅲb-Ⅳ grade non-small cell lung cancer patients were divided randomly and double-blind method into control group including 25 patients and therapy group including 25patients.For therapy group,gemcitabine was used by 1000mg/m 2 vein drip at 1st and 8th day,carboplatin was used by 300mg/m 2 at 1st day, 4 weeks was a cycle; for control group,etoplside was used by 0.1/m 2 vein drit at 1st,2nd and 3rd day,carboplatin was used by 300mg/m 2 at 1st day,4 weeks was a cycle.After 2 cycles,curative effect was observed.Results In therapy group,6 patients were completely remission and 8 patients were partly remission,effective rate was 56%,middle term of remission was 3.8 months;In control group,2 patients were completely remission and 7 patients were partly remission,effective rate was 36%.Conclusion gemcitabine and carboplatin is a better therapeutic alliance method on non-small cell lung cancer patients. [
出处
《现代肿瘤医学》
CAS
2004年第2期133-134,共2页
Journal of Modern Oncology
